Grants Search Results

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer, perhaps encouraging the future choice of childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer, perhaps encouraging the future choice of childhood cancer research as a specialty.

Based on progress to date, Dr. Engel was awarded a new grant in 2013 to fund an additional two years of this Scholar award. Approximately one thousand children are diagnosed with acute myeloid leukemia (AML) each year in the United States, and only about 50% survive. Dr. Engel's research is to gain a better understanding of how normal blood cell development is altered in AML and how we can overcome these alterations to regain control over blood cell growth and development. Dr. Engel began his research at Vanderbilt University Medical Center and moved to the Huntsman Cancer Institute in 2010.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

Based on progress to date, Dr. Federman was awarded a new grant in 2012 to fund an additional two years of this Scholar award. We already have many powerful drugs to treat cancer but lack the means to deliver them directly to the intended targets (cancer cells), and as a result, cancer patients suffer significant side effects. Dr. Federman tests new ways of delivering anti-cancer treatments more directly using nanoparticles programmed to recognize particular cancer cells.

This grant helps provide staffing to ensure that more kids can be treated on clinical trials, their best hope for a cure, at this institution. A Clinical Research Associate is involved not in the child's treatment, but in the opening of clinical trials and coordinating the collection and submission of bodily tissues and information for each child on a clinical trial. Without these crucial functions, which are often hard to fund, clinical trials cannot continue to advance toward cures, and children are not offered the most up-to-date treatment options.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

The goal of this proposal is to identify tumor suppressor genes that are "turned off" by DNA methylation and contribute to the formation of Ewing Sarcoma, a type of bone cancer that affects teenagers and young adults. This study searches for a better understanding of Ewing Sarcoma and the development of better treatments.

Based on progress to date, Dr. Arvanitis was awarded a new grant in 2011 to fund an optional third year of this fellowship. Osteosarcoma is the most common pediatric bone cancer, which frequently spreads (or metastasizes) to the lung and is then often fatal. Dr. Arvanitis is studying the role of transendothelial migration in osteosarcoma, with the ultimate goal of developing therapies against metastases in pediatric cancers.

The Ewings sarcoma family of tumors (ESFTs) is the second most common cancer of bone and soft tissue in children, and has a 20-30% overall survival rate in those children with widespread disease. Dr. Dela Cruz is working to understand the pathways involved in the development of ESFTs, which will be essential to discovering new molecular targets to treat and cure these patients.

Based on progress to date, Dr. Mulcahy-Levy was awarded a new grant in 2011 to fund an optional third year of this fellowship. Understanding how cancer cells die is important in designing new therapies and improving the effectiveness of currently used therapies to cure childhood cancers. One element of cell death is called autophagy, a system the cell uses to break down as it dies, the focus of Dr. Mulcahy-Levy's project.

This research focuses on hematopoietic progenitor/stem cell (HPC) transplantation. (These stem cells are not embryonic; they are present in everyone's bone marrow and can be harvested from donors.) Dr. Parekh is working on methods to expand HPC to facilitate the use of cord blood and the use of gene therapy to treat leukemia, an important step toward a cure.